Spots Global Cancer Trial Database for elotuzumab
Every month we try and update this database with for elotuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | NCT03252600 | Recurrent Prima... | Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | NCT03411031 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Combination Study for High Risk Multiple Myeloma Patients | NCT03104270 | Multiple Myelom... | Elotuzumab Pomalidomide Carfilzomib Dexamethasone | 18 Years - | Oncotherapeutics | |
| 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | NCT03003728 | Multiple Myelom... | Elotuzumab Melphalan Autologous Stem... Expanded Natura... ALT-803 | 18 Years - 75 Years | University of Arkansas | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft | NCT03393273 | Multiple Myelom... | Elotuzumab | 66 Years - | Assistance Publique - Hôpitaux de Paris | |
| PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | NCT01891643 | Newly Diagnosed... | Lenalidomide Dexamethasone Elotuzumab | 18 Years - | Bristol-Myers Squibb | |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | NCT03030261 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone | 18 Years - 75 Years | Washington University School of Medicine | |
| Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | NCT02969837 | Multiple Myelom... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | NCT03361306 | Multiple Myelom... | Elotuzumab | 18 Years - | Wake Forest University Health Sciences | |
| 2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | NCT03000634 | Multiple Myelom... | Elotuzumab Bortezomib Lenalidomide Dexamethasone | 18 Years - 75 Years | University of Arkansas | |
| Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | NCT02843074 | Multiple Myelom... | elotuzumab Lenalidomide Dexamethasone autologous stem... | 18 Years - | SCRI Development Innovations, LLC | |
| Early Patient Access Treatment Use Protocol CA204-220 | NCT02856438 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 20 Years - | Bristol-Myers Squibb | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | NCT03361306 | Multiple Myelom... | Elotuzumab | 18 Years - | Wake Forest University Health Sciences | |
| Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01729091 | Plasma Cell Leu... Plasma Cell Mye... | Autologous Hema... Elotuzumab Laboratory Biom... Lenalidomide Melphalan Natural Killer ... Umbilical Cord ... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | NCT02279394 | Smoldering Myel... Smoldering Mult... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | NCT01891643 | Newly Diagnosed... | Lenalidomide Dexamethasone Elotuzumab | 18 Years - | Bristol-Myers Squibb | |
| A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | NCT02495922 | Multiple Myelom... | elotuzumab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06158841 | Multiple Myelom... | ABBV-383 Carfilzomib Pomalidomide Elotuzumab Selinexor Bortezomib Dexamethasone | 18 Years - | AbbVie | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | NCT03227432 | Multiple Myelom... | Dexamethasone Pomalidomide Elotuzumab Nivolumab | 18 Years - | Dana-Farber Cancer Institute | |
| Early Patient Access Treatment Use Protocol CA204-220 | NCT02856438 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 20 Years - | Bristol-Myers Squibb | |
| A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | NCT02718833 | Multiple Myelom... | Elotuzumab Pomalidomide Bortezomib Dexamethasone | 18 Years - | Massachusetts General Hospital | |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | NCT03030261 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone | 18 Years - 75 Years | Washington University School of Medicine | |
| Combination Study for High Risk Multiple Myeloma Patients | NCT03104270 | Multiple Myelom... | Elotuzumab Pomalidomide Carfilzomib Dexamethasone | 18 Years - | Oncotherapeutics | |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | NCT02726581 | Multiple Myelom... | Nivolumab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | NCT05981209 | Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dexamethasone Echocardiograph... Elotuzumab Magnetic Resona... Mezigdomide X-Ray Imaging | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | NCT05730036 | Relapsed Refrac... | Linvoseltamab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Regeneron Pharmaceuticals | |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | NCT05730036 | Relapsed Refrac... | Linvoseltamab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | NCT02612779 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | NCT02495922 | Multiple Myelom... | elotuzumab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | NCT02726581 | Multiple Myelom... | Nivolumab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Early Patient Access Treatment Use Protocol CA204-220 | NCT02856438 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 20 Years - | Bristol-Myers Squibb | |
| Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06158841 | Multiple Myelom... | ABBV-383 Carfilzomib Pomalidomide Elotuzumab Selinexor Bortezomib Dexamethasone | 18 Years - | AbbVie | |
| A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | NCT05028348 | Multiple Myelom... | Selinexor Elotuzumab Pomalidomide Dexamethasone O... | 18 Years - | Stichting European Myeloma Network | |
| Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT02420860 | Hematopoietic C... Plasma Cell Mye... | Elotuzumab Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | NCT04517851 | Myelofibrosis T... Polycythemia Ve... Primary Myelofi... | Elotuzumab Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | NCT02159365 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | NCT03168100 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone Bortezomib | 18 Years - 75 Years | University of Arkansas | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | NCT03713294 | Refractory Plas... | Dexamethasone Elotuzumab Pomalidomide | 18 Years - | Mayo Clinic | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | NCT03023527 | Multiple Myelom... | Nivolumab Pomalidomide Dexamethasone Elotuzumab | 18 Years - | PETHEMA Foundation | |
| A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | NCT02718833 | Multiple Myelom... | Elotuzumab Pomalidomide Bortezomib Dexamethasone | 18 Years - | Massachusetts General Hospital | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant | NCT04584307 | Multiple Myelom... | Elotuzumab Pomalidomide | 18 Years - | Big Ten Cancer Research Consortium | |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | NCT02726581 | Multiple Myelom... | Nivolumab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Combination Study for High Risk Multiple Myeloma Patients | NCT03104270 | Multiple Myelom... | Elotuzumab Pomalidomide Carfilzomib Dexamethasone | 18 Years - | Oncotherapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
